A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
- Registration Number
- NCT03535194
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1484
- Participant must have chronic plaque psoriasis for at least 6 months.
- Participant must not be breastfeeding or nursing woman.
- Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.
- Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.
- Participant must not have any other skin conditions (excluding psoriasis).
- Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).
- Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.
- Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo/250mg Mirikizumab Placebo Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab. 300mg Secukinumab Secukinumab Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period. 250mg Q4W/125mg Q8W Mirikizumab Mirikizumab Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab. 250mg Q4W/250mg Q8W Mirikizumab Mirikizumab Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab. Placebo/250mg Mirikizumab Mirikizumab Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab. Japan GPP/EP Mirikizumab Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.
- Primary Outcome Measures
Name Time Method Percentage of Participants With a Static Physician's Global Assessment (sPGA) of (0,1) With at Least a 2-point Improvement From Baseline Week 16 The sPGA is the physician's determination of the participant's psoriasis lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's psoriasis was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline Week 16 PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
- Secondary Outcome Measures
Name Time Method Change From Baseline for the Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI-PSO) Scores Baseline, Week 16 The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100) with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.
Change From Baseline in Quick Inventory of Depressive Symptomatology (QIDS-SR16) Total Score in Those With a Baseline QIDS-SR16 Total Score ≥11. Baseline, Week 16 QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. Whereas 0-5 indicates no symptoms.
Percentage of Participants Achieving a 75% Improvement in PASI 75 Week 16 PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
Percentage of Participants With ≤1% of Body Surface Area (BSA) With Psoriasis Involvement Week 16 The BSA is the percentage involvement of psoriasis on each participant's body surface on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including the palm, fingers, and thumb). The total BSA affected was the summation of individual regions affected. Percentage response is calculated by number of participants with a response divided by number of participants with non-missing values multiplied by 100.
Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline Baseline, Week 16 The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline Baseline, Week 16 The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix PsO by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed PsO 0 (none) to 4 (PsO in 4 quadrants of the fingernail) and fingernail matrix PsO 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix PsO in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of (0,1) With at Least a 2-point Improvement From Baseline (Non-inferiority) Week 16 The sPGA is the physician's determination of the participant's psoriasis lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's psoriasis was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 in Those With PSS Symptom Score of ≥1 at Baseline Week 16 PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. In addition, a symptoms score ranging from 0 (no symptoms) to 40 (worst imaginable symptoms), and a signs score of 0 (no signs) to 30 (worst imaginable signs) will be reported. Percentage response is calculated by number of participants with a response divided by number of participants with non-missing values multiplied by 100.
Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline Baseline, Week 16 The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Least Squares Mean (LS Mean) was calculated using mixed model repeated measures (MMRM) model with treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, and previous exposure to biologic therapy (yes/no), body weight (\<100 kg or \>=100 kg), and geographic region (North America or Other) as covariates.
Percentage of Participants Achieving Patient's Global Assessment (PatGA) of Disease Severity of (0,1) With at Least a 2-point Improvement From Baseline in Patients With a Baseline PatGA ≥2 Week 16 The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). Percentage response is calculated by number of participants with a response divided by number of participants with non-missing values multiplied by 100.
Pharmacokinetics: Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Mirikizumab Week 16 Minimum observed serum Ctrough,ss of mirikizumab
Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline (Non-inferiority) Week 16 PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥5 Week 16 The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). A DLQI total score of 0 to 1 is considered as having no effect on a patient's health-related quality of life (HRQoL), and a 5-point change from baseline is considered as the minimal clinically important difference (MCID) threshold. Percentage response is calculated by number of participants with a response divided by number of participants with non-missing values multiplied by 100.
Change From Baseline on the 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS) Baseline, Week 16 SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health.
Change From Baseline on the SF-36 Mental Component Summary (MCS) Baseline, Week 16 SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health.
Trial Locations
- Locations (177)
Clinical Trials SA Pty Ltd
🇦🇺Adelaide, South Australia, Australia
Dawes Fretzin Clinical Research
🇺🇸Indianapolis, Indiana, United States
Dermatology Associates
🇺🇸Seattle, Washington, United States
Centrum Medyczne Angelius Provita
🇵🇱Katowice, Slaskie, Poland
Texas Dermatology and Laser Specialists
🇺🇸San Antonio, Texas, United States
Tokyo Medical University Hospital
🇯🇵Shinjuku-ku, Tokyo, Japan
St. Lukes International Hospital
🇯🇵Chuo-Ku, Tokyo, Japan
Nihon University Itabashi Hospital
🇯🇵Itabashi-ku, Tokyo, Japan
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Teikyo University Hospital
🇯🇵Itabashi-ku, Tokyo, Japan
Universitätsklinikum Schleswig-Holstein
🇩🇪Lübeck, Schleswig-Holstein, Germany
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Hautarztpraxis Dr. Leitz und Kollegen
🇩🇪Stuttgart, Baden-Württemberg, Germany
Universitätsklinikum Tübingen
🇩🇪Tübingen, Baden-Württemberg, Germany
Tien Q. Nguyen, MD inc. DBA First OC Dermatology
🇺🇸Fountain Valley, California, United States
California Dermatology and Clinical Research Institute
🇺🇸Encinitas, California, United States
Dermatology Clinical Trials
🇺🇸Newport Beach, California, United States
Arlington Dermatology
🇺🇸Rolling Meadows, Illinois, United States
The South Bend Clinic
🇺🇸South Bend, Indiana, United States
Wright State Physicians Dermatology
🇺🇸Fairborn, Ohio, United States
Virginia Clinical Research
🇺🇸Norfolk, Virginia, United States
Dr. Chih-ho Hong Medical Inc.
🇨🇦Surrey, British Columbia, Canada
CHU Dupuytren 2
🇫🇷Limoges, Cedex, France
Elbe Kliniken Stade Buxtehude GmbH Klinikum Buxtehude
🇩🇪Buxtehude, Niedersachsen, Germany
Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem, o.z.
🇨🇿Usti nad Labem, Ustecký Kraj, Czechia
Skin and Cancer Foundation Inc.
🇦🇺Carlton, Victoria, Australia
Stratica Medical
🇨🇦Edmonton, Alberta, Canada
Fremantle Dermatology
🇦🇺Perth, Western Australia, Australia
Cabinet Médical
🇫🇷Martigues, France
Hopital Saint Eloi
🇫🇷Montpellier, France
CH du Mans - Pavillon Claude Monet
🇫🇷Le Mans Cedex 1, France
Clintrial, s.r.o.
🇨🇿Praha 10, Hl. M. Praha, Czechia
Soroka Medical Center
🇮🇱Beer Sheva, Israel
Kozni oddeleni
🇨🇿Novy Jicin, Czechia
Lynderm Research Inc
🇨🇦Markham, Ontario, Canada
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
🇩🇪Frankfurt am Main, Hessen, Germany
TFS Trial Form Support GmbH
🇩🇪Hamburg, Germany
UNO Medical Trials Kft.
🇭🇺Budapest, Hungary
Policlinico Univ. Agostino Gemelli
🇮🇹Roma, Rome, Italy
Rambam Medical Center
🇮🇱Haifa, Israel
Rabin Medical Center
🇮🇱Petach Tikva, Israel
Istituto Clinico Humanitas
🇮🇹Rozzano, Milano, Italy
Policlinico di Tor Vergata
🇮🇹Roma, Italy
Nagoya City University Hospital
🇯🇵Nagoya, Aichi, Japan
Presidio Ospedaliero Firenze Centro Piero Palagi
🇮🇹Firenze, Italy
Asahikawa Medical College Hospital
🇯🇵Asahikawa, Hokkaido, Japan
Tohoku University Hospital
🇯🇵Sendai, Miyagi, Japan
Shiga University of Medical Science Hosptial
🇯🇵Ohtsu-shi, Shiga, Japan
Shinshu University Hospital
🇯🇵Matsumoto, Nagano, Japan
Korea University Guro Hospital
🇰🇷Seoul, Korea, Korea, Republic of
Ryukyu University Hospital
🇯🇵Nakagami-gun, Okinawa, Japan
The University of Tokyo Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
Hospital de Manises
🇪🇸Manises, Valencia, Spain
Office of Dr. Alma M. Cruz
🇵🇷Carolina, Puerto Rico
NZOZ ZDROWIE Osteo-Medic
🇵🇱Bialystok, Podlaskie, Poland
Hospital Marina Baixa
🇪🇸Villajoyosa, Alicante, Spain
Centralny Szpital Kliniczny MSW Klinika Dermatologii
🇵🇱Warszawa, Mazowieckie, Poland
Centrum Medyczne Evimed
🇵🇱Warszawa, Mazowieckie, Poland
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital De Basurto
🇪🇸Bilbao, Vizcaya, Spain
Gifu University Hospital
🇯🇵Gifu, Japan
Showa University Hospital
🇯🇵Shinagawa-ku, Tokyo, Japan
Barbara Rewerska DIAMOND CLINIC
🇵🇱Krakow, Malopolskie, Poland
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Korea, Republic of
Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Infanta Leonor
🇪🇸Madrid, Spain
NZOZ Specjalistyczna Przychodnia Dermatologiczna Specderm
🇵🇱Bialystok, Podlaskie, Poland
Ponce School of Medicine CAIMED Center
🇵🇷Ponce, Puerto Rico
Lubelskie Centrum Diagnostyczne
🇵🇱Swidnik, Lubelskie, Poland
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Spain
Centrum Badan Klinicznych, PI House
🇵🇱Gdansk, Pomorskie, Poland
Dermed Centrum Medyczne Sp. z o.o.
🇵🇱Lodz, Lodzkie, Poland
Santa Cruz Behavioral PSC
🇵🇷Bayamón, Puerto Rico
Office of Dr. Samuel Sanchez PSC
🇵🇷Caguas, Puerto Rico
Hospital Germans Trias i Pujol
🇪🇸Barcelona, Badalona, Spain
Hospital Reina Sofia
🇪🇸Cordoba, Spain
LASER CLINIC Specjalistyczne Gabinety Lekarskie
🇵🇱Szczecin, Zachodniopomorskie, Poland
Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
🇵🇱Lodz, Poland
AI Centrum Medyczne
🇵🇱Poznan, Poland
Hospital Universitario La Fe de Valencia
🇪🇸Valencia, Spain
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
CHU de Bordeaux Hopital Saint Andre
🇫🇷Bordeaux Cedex, France
K. Papp Clinical Research Inc
🇨🇦Waterloo, Ontario, Canada
Innovaderm Research Inc
🇨🇦Montreal, Quebec, Canada
Nagasaki University Hospital
🇯🇵Nagaski, Japan
Wakayama MedicaL University Hospital
🇯🇵Wakayama, Japan
Pusan National University Hospital
🇰🇷Busan, Korea, Korea, Republic of
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Centro de Especialidades Mollabao
🇪🇸Pontevedra, Spain
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Bacs-Kiskun Megyei Korhaz
🇭🇺Kecskemet, Bacs-Kiskun, Hungary
Park Avenue Dermatology
🇺🇸Orange Park, Florida, United States
Clinical Science Institute
🇺🇸Santa Monica, California, United States
Meridian Clinical Research
🇺🇸Savannah, Georgia, United States
Dermatologic Surgery Specialists, PC
🇺🇸Macon, Georgia, United States
Medaphase Inc
🇺🇸Newnan, Georgia, United States
The Indiana Clinical Trials Center, PC
🇺🇸Plainfield, Indiana, United States
Dermatology Specialist
🇺🇸Louisville, Kentucky, United States
Lawrence J Green, M.D, LLC
🇺🇸Rockville, Maryland, United States
Dermatology and Skin Cancer Specialists
🇺🇸Rockville, Maryland, United States
ORA, Inc
🇺🇸Andover, Massachusetts, United States
Psoriasis Treatment Center of Central New Jersey
🇺🇸East Windsor, New Jersey, United States
University of North Carolina Dermatology and Skin Cancer Cen
🇺🇸Chapel Hill, North Carolina, United States
Mount Sinai School of Medicine Dermatology Clinical Trials
🇺🇸New York, New York, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
PMG Research of Wilmington, LLC
🇺🇸Wilmington, North Carolina, United States
Oregon Dermatology and Research Center
🇺🇸Portland, Oregon, United States
Austin Institute for Clinical Research, Inc.
🇺🇸Pflugerville, Texas, United States
Centro de Investigaciones Metabólicas (CINME)
🇦🇷Buenos Aires, Argentina
Buenos Aires Skin
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Instituto de Neumonología y Dermatología
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
CEDIC-Centro de Investigaciones Clinicas
🇦🇷Caba, Buenos Aires, Argentina
Psoriahue Medicina Interdisciplinaria
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Clinica Adventista de Belgrano
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Halitus Instituto Médico
🇦🇷Ciudad Autonoma de Buenos Aire, Argentina
Veracity Clinical Research Pty Ltd
🇦🇺Woolloongabba, Queensland, Australia
Parra Dermatología
🇦🇷Mendoza, Argentina
Eastern Canada Cutaneous Research Assoicates Ltd
🇨🇦Halifax, Nova Scotia, Canada
SKiN Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha 10, Hl. M. Praha, Czechia
Kozni ambulance Kutna Hora, s.r.o.
🇨🇿Kutna Hora, Středočeský Kraj, Czechia
Hopital Larrey
🇫🇷Toulouse cedex 9, France
CHU de Nice Hopital de L'Archet
🇫🇷Nice cedex 3, France
Chu de Rouen Hopital Charles Nicolle
🇫🇷Rouen cedex, France
Rothhaar Studien GmbH
🇩🇪Berlin, Germany
Klin. Forschung Berlin-Mitte GmbH
🇩🇪Berlin, Germany
Fachklinik Bad Bentheim
🇩🇪Bad Bentheim, Nordrhein-Westfalen, Germany
Oroshaza Varosi Onkormanyzat Korhaza
🇭🇺Oroshaza, Hungary
Debreceni Egyetem Klinikai Kozpont Borgyogyaszati Klinika
🇭🇺Debrecen, Hajdu-Bihar, Hungary
Trial Pharma Kft.
🇭🇺Puspokladany, Hajdu-Bihar, Hungary
Allergo-Derm Bakos Kft
🇭🇺Szolnok, Jasz-Nagykun-Szolnok, Hungary
MedMare Bt
🇭🇺Veszprem, Hungary
Haemek Medical Center- Dermatology
🇮🇱Afula, Israel
Juntendo Urayasu Hospital
🇯🇵Urayasu, Chiba, Japan
Kurume University Hospital
🇯🇵Kurume, Fukuoka, Japan
Gunma University Hosptial
🇯🇵Maebashi, Gunma, Japan
Tokai University Hospital
🇯🇵Isehara, Kanagawa, Japan
Tokyo Medical University Ibaraki Medical Center
🇯🇵Inashiki-gun, Ibaraki, Japan
Kyoto Prefectural University of Medicine
🇯🇵Kyoto-shi, Kyoto, Japan
Mie University Hospital
🇯🇵Tsu, Mie, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Osaka, Japan
Yamanashi Prefectural Central Hospital
🇯🇵Kofu, Yamanashi, Japan
Yamaguchi University Hospital
🇯🇵Ube, Yamaguchi, Japan
Nippon Life Hospital
🇯🇵Osaka, Japan
Ilsan Paik Hospital
🇰🇷IlsanSeo-gu, Goyang-si, Korea, Republic of
Osaka City University Hospital
🇯🇵Osaka, Japan
Tokushima University Hospital
🇯🇵Tokushima, Japan
Samsung Medical Center
🇰🇷Seoul, Korea, Korea, Republic of
DermMEDICA Sp. z o.o.
🇵🇱Wroclaw, Dolnoslaskie, Poland
DermoDent, Centrum Medyczne Czajkowscy
🇵🇱Osielsko, Kujawsko-pomorskie, Poland
Chungang University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
GCM Medical Group PSC
🇵🇷San Juan, Puerto Rico
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
PMG Research of Cary, LLC
🇺🇸Cary, North Carolina, United States
Modern Research Associates PLLC
🇺🇸Dallas, Texas, United States
Jordan Valley Dermatology Center
🇺🇸West Jordan, Utah, United States
Bakersfield Dermatology and Skin Cancer Medical Group
🇺🇸Bakersfield, California, United States
Keck School of Medicine University of Southern California
🇺🇸Los Angeles, California, United States
David Stoll, M.D.
🇺🇸Beverly Hills, California, United States
San Luis Dermatology & Laser Clinic, Inc
🇺🇸San Luis Obispo, California, United States
DelRicht Research
🇺🇸Baton Rouge, Louisiana, United States
Treasure Valley Dermatology
🇺🇸Boise, Idaho, United States
Bexley Dermatology Research
🇺🇸Bexley, Ohio, United States
Central Dermatology PC
🇺🇸Saint Louis, Missouri, United States
Konkuk University Medical Center
🇰🇷Seoul, Korea, Republic of
The Guenther Dermatology Research Centre
🇨🇦London, Ontario, Canada
University Dermatology
🇺🇸Darien, Illinois, United States
Dermatologisches Zentrum Osnabrück Nord
🇩🇪Bramsche, Niedersachsen, Germany
Clinical Partners LLC
🇺🇸Johnston, Rhode Island, United States
Fakultni Nemocnice U svate Anny
🇨🇿Brno, Jihomoravský Kraj, Czechia
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH
🇩🇪Darmstadt, Hessen, Germany
Ambrozia Kft.
🇭🇺Budapest, Hungary
Salford Royal NHS Foundation Trust
🇬🇧Salford, Greater Manchester, United Kingdom
Woden Dermatology
🇦🇺Phillip, Australian Capital Territory, Australia
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Baden-Württemberg, Germany